- Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel Gilead Sciences
- This Biotech Stock Is Having Its Best Day Ever. Gilead Sciences Is Buying It. Barron’s
- Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion Reuters
- Here’s Why Shares of Arcellx Are Up Almost 80% Today Yahoo Finance
- Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion WSJ